2024 MARATHON OF HOPE CLINICIAN SCIENTIST AWARD
To provide outstanding young clinician investigators with funding to support high quality research in precision oncology. The award is designed to support young investigators as they develop their careers as independent clinician scientists, in close collaboration and mentorship with established Marathon of Hope Cancer Centres Network (MOHCCN) funded-teams.
Support under this Request for Applications (RFA) is targeted at high-quality, clinically-related research, providing information that may form the basis of innovative cancer prevention, diagnosis and/or treatment. In general research supported by these awards should include, but may not be limited to studies that develop new:
- ways of generating therapeutically actionable biological cancer data
- types of therapeutically actionable biological cancer data
- tools to analyze existing rich, complex or large datasets, and
- precision oncology trial design, conduct and analysis.
Applicants must be mentored by researcher(s) (clinician and/or scientist) currently associated with a MOHCCN-funded study. Special consideration will be afforded to applicants who include plans for inclusion of marginalized populations in their work.
Up to four awards of $75,000 each per annum are tenable for three years and provide:
- Approved research expenses for the research project awarded.
The sponsoring, eligible Canadian institution is encouraged to match the Marathon of Hope Clinician Scientist Award with a similar amount to be used to augment research expenses. Up to four awards will be made for this round of the competition. We expect to announce additional rounds in subsequent years.
To apply you should:
- Be a physician (MD, or international equivalent) and are eligible to start, continue, or have completed their subspeciality training (medical oncology, hematology-oncology, pediatric oncology, surgical oncology, radiation oncology and pathology, etc.)
- Have completed MD or MD PhD degrees by the time the award is taken up
- Be a Canadian citizen or a Permanent Resident of Canada
- Have a valid, active Canadian medical licence
- Be within the first five calendar years of their first faculty appointment at an eligible Canadian hospital or academic health sciences centre
- Be planning an investigative career in clinical oncology
- Have a mentor in the proposed research field from the sponsoring Institution. The mentor must assume responsibility and provide guidance for the research
- Not currently be holding a Terry Fox Research Institute New Investigator Award
- Have a letter of commitment from the eligible Canadian hospital or academic health sciences centre
- confirming the date of appointment of the applicant which can EITHER be no more than one year later than the start of the award OR be no more than five calendar years before the start of the award, and
- indicate provision of direct support for the applicant to spend dedicated time for research.
The MOHCCN has an initial funding envelope sufficient to fund up to four Marathon of Hope Clinician Scientist Awards awards in the first round.
Key Deadlines and Dates
|Registration of Intent
|Monday, December 18, 2023 (5:00pm EST)
|Submission of a Full Application
|Friday, February 9th, 2024 (5:00pm EST)
|Peer Review Committee Meeting
|July 1, 2024
Please refer to the following documents for guidance:
- 2024 MOHCCN Clinician-Scientist: REQUEST FOR APPLICATIONS: EN | FR
- 2024 MOHCCN Clinician-Scientist: REGISTRATION OF INTENT: EN | FR
- 2024 MOHCCN Clinician-Scientist: CV: EN | FR
- 2024 MOHCCN Clinician-Scientist: FULL APPLICATION: EN |FR
- 2024 MOHCCN Clinician-Scientist: FULL APPLICATION GUIDE: EN | FR
Jessie Micholuk, MPH
Network Programs Manager, MOHCCN
Currently Funded Clinician-Scientist Award Projects
YEAR 1 PROJECTS
- Dr. Ana Nikolic, University of Calgary (Calgary) for: The evolution of transcriptional cellular state dynamics in recurrent glioblastoma
- Dr. Robert Grant, University Health Network (Toronto) for: Mapping pancreatic cancer biology to drug responses
- Dr. Bertrand Routy, Centre de Recherche du Centre hospitalier de l'Université de Montréal (Montreal) for: How microbiomes influence intratumour immune contexture and response to immune-checkpoint inhibitors in patients with non-small cell lung cancer
- Dr. Philippe Lefrançois, Lady Davis Institute, McGill University and Jewish General Hospital (Montreal) for: Understanding the genomic and cellular landscapes of advanced basal cell carcinoma (BCC)
YEAR 2 PROJECTS
- Dr. Houda Bahig, Centre de Recherche du Centre hospitalier de l'Université de Montréal (Montreal) for: Artificial intelligence to predicting efficacy of drugs and radiation in head and neck cancer through radiology imaging and digital pathology combined to tumour genomics
- Dr. Long Viet Nguyen, University Health Network (Toronto): Predicting drug response of molecular clones in triple-negative breast cancer
- Dr. Natasha Szuber, Hôpital Maisonneuve-Rosemont (Montreal): Defining the genomic landscape of high-risk hyperproliferative phenotypes in polycythemia vera: A precision medicine-based approach
- Dr. Basile Tessier-Cloutier, Research Institute of the McGill University Health Centre (Montreal): Clinicopathologic and molecular characterization informs large-scale therapeutic screening of SWI/SNF-deficient gynecologic malignancies